Following a public comment period, the USA’s Federal Trade Commission has approved a final order settling charges that Swiss pharma major Novartis’ (NOVN: VX) $16 billion acquisition of UK peer GlaxoSmithKline’s (LSE: GSK) portfolio of cancer-treatment drugs likely would be anticompetitive.
Under the order first announced earlier (The Pharma Letter February 24), Novartis has agreed to divest all assets related to its BRAF- and MEK-inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma.
According to the complaint, since Novartis and GSK are two of a small number of companies holding BRAF or MEK inhibitors either on the market or in development, and two of three marketing or developing a combination product for melanoma, it would breach competition requirements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze